micro-community-banner
 
  • Saved

2yr
Cell-based gene therapy in multiple myeloma

The CAR T-cell field in MM has made several strides since the first BCMA-targeted CAR was developed nearly 10 years ago. Results from the pivotal phase 2 KarMMa study of idecabtagene vicleucel (ide-cel) shows promise with rapid, deep, and durable responses in patients with triple-class-exposed relapsed and refractory myeloma.

The ORR at primary analysis was 72% at a median follow-up of 13.2 months. Furthermore, 55% of patients experienced a very good partial response (VGPR) or better, with 93% of evaluable patients being MRD negative.

Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It is indicated in adult patients with R/R multiple myeloma following 4+ prior lines of therapy. These prior lines of therapy include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Ide-cel was approved by the FDA in March 2021, and each dose is a customized treatment developed based on the patient’s own T-cells. These T-cells are collected and genetically modified to incorporate a new gene that targets and kills myeloma cells. Modified cells are infused into the patient.

What have your experiences with ide-cel been compared with other BRMA-targeted CAR T cell therapy? In your opinion/experience, will ide-cel have a prominent place in R/R multiple myeloma?

  • 2yr
    Carvyktri seems to outperform Abecma in OS, PFS, ORR but usage has been heavily limited my manufacturing slot availability. Have used both CAR-T products in place of transplant for good Show More
  • 2yr
    i think Ide-Cel has potential role IN THE PLACE OF TRANSPLANT /instead of transplant; otherwise, its a very valuable tretament option; concern si getting slots, enrollment speed is a concern(slow Show More

Show More Comments

  • Saved

2yr
Influence of diabetes mellitus on the biochemical parameters and outcomes of multiple myeloma - PubMed

Influence of diabetes mellitus on the biochemical parameters and outcomes of multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36799658/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....


Conclusions: There was no significant difference between the three groups in the incidence of hypercalcemia, anemia, and renal function impairment. The survival time of patients with DM was shorter than that of patients without DM.


  • Saved

2yr
Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - PubMed

Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36794354/

Idecabtagene vicleucel (ide-cel; bb2121) is a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This...


Conclusions: The established ER models were used to quantify the ide-cel dose–response, which showed a positive benefit–risk assessment for the range of ide-cel exposures associated with the target dose range of 150–450 × 106 CAR T cells.


  • Saved

2yr
Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy

Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy

Source : https://www.sciencedirect.com/science/article/abs/pii/S2452318623000028?via=ihub

Chimeric antigen receptor T-cell (CAR-T) therapy has been proven very effective in treating . Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double hematologic malignancies B cell maturation antigen (BCMA)...


Conclusions: Our results suggested that serum sBCMA level changes in response to the clinical status of MM patients after anti-BCMA CAR-T therapy. Furthermore, sBCMA may be a auxiliary biomarker for disease monitoring in MM patients after CAR-T therapy.

  • Saved

2yr
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma - PubMed

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36762851/

Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class-exposed relapsed and refractory multiple myeloma who had received two to four regimens...


Conclusions: Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma who had received two to four regimens previously. The toxicity of ide-cel was consistent with previous reports.